Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10820988 | 0.67 | POLB (0.32) | PTPRC | |
| SCHEMBL2821671 | 0.67 | PTPRC (0.31) | PTPRC | |
| SCHEMBL6052670 | 0.64 | PTPRC (0.45) | PTPRC | |
| SCHEMBL353445 | 0.62 | PTPRC (0.31) | PTPRC | |
| SCHEMBL15844709 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL8973466 | 0.61 | PTPRC (0.31) | PTPRC | |
| SCHEMBL50865 | 0.61 | MAOA (0.50) | PTPRC | |
| SCHEMBL31414587 | 0.61 | — | — | |
| SCHEMBL13315856 | 0.60 | PTPRC (0.32) | PTPRC | |
| Hydrochloric Acid SCHEMBL2710069 | 0.60 | MAOA (0.48) | PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0466730-B1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1993-07-21 | — | — | EP | claimed |
| US-11427673-B2 | Alternative crosslinking mechanisms for polyurethane-based systems | COVESTRO LLC (US) | 2022-08-30 | — | — | US | disclosed |
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-20200255578-A1 | ALTERNATIVE CROSSLINKING MECHANISMS FOR POLYURETHANE-BASED SYSTEMS | COVESTRO LLC | 2020-08-13 | — | — | US | disclosed |
| CN-108017606-A | Compound and organic electroluminescent element containing same | 株式会社LG化学 | 2018-05-11 | — | — | CN | disclosed |
| US-20160205925-A1 | ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2016-07-21 | — | — | US | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| US-20100247447-A1 | DRUG DELIVERY SYSTEM FOR HYDROPHOBIC DRUGS | BAUSCH HEALTH COMPANIES INC. (CA) | 2010-09-30 | — | — | US | disclosed |
| US-20090192209-A1 | Extended treatment of tumors through vessel occlusion with light activated drugs | LIGHT SCIENCES ONCOLOGY, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062384-A2 | REDUCED FLUENCE RATE PDT | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062385-A2 | METHOD TO PREVENT VISION LOSS | QLT, INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| EP-1229937-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT Inc. (CA) | 2002-08-14 | — | — | EP | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001085213-A2 | SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085212-A2 | DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001035996-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001035997-A2 | USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192209-A1 | Extended treatment of tumors through vessel occlusion with light activated drugs | PTGIR, TEK, FLT4 | PTPRC 1189/4885 |
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | PTPRC 1935/4885 |
| US-20100247447-A1 | DRUG DELIVERY SYSTEM FOR HYDROPHOBIC DRUGS | LIPA, MLEC, ABCG2 | PTPRC 2571/4885 |
| US-20160205925-A1 | ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER | CUTA, POLR1C, PUF60 | PTPRC 3112/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | PTPRC 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.